PolyPeptide Group AG (LTS:0AAJ) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AAJ PolyPeptide Group AG LTS:0AAJ
57 GF Score
Price CHF45.58
GF Value CHF30.98
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0AAJ vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPeptide Group AG Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's Short Interest distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's Short Interest falls into.


LTS:0AAJ
57GF Score
PolyPeptide Group AG LTS:0AAJ
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PolyPeptide Group AG (LTS:0AAJ) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF45.58 is trading 47.1% above its estimated GF Value™ of CHF30.98. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for LTS:0AAJ:

  • Short Interest:
  • GF Value™: CHF30.98 vs. price of CHF45.58 (47.1% above fair value)
  • GF Score™: 57/100 with 9 warning signs

No single metric tells the full story. See the LTS:0AAJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
57GF Score

Get the complete analysis for LTS:0AAJ

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF45.58
Price
CHF30.98
GF Value